Literature DB >> 11407087

T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen.

R Giacomelli1, A Passacantando, R Perricone, I Parzanese, M Rascente, G Minisola, G Tonietti.   

Abstract

OBJECTIVE: To assess the percentage of T lymphocytes, bearing CD134, a member of the TNF receptor superfamily, primarily found on autoreactive CD4+ T cells in the peripheral blood (PB) and synovial fluid (SF) of rheumatoid arthritis (RA) patients.
METHODS: The surface expression of CD134 on SF and PB mononuclear cells was performed by flow cytometry in 25 RA patients and correlated to the disease activity.
RESULTS: CD134 expression on CD3+, CD4+, CD8+ and CD25+ cells was higher in SF than in PB of RA patients (P < 0.001). No differences were observed in the percentage of CD134+/CD4+ T lymphocytes in the PB of RA patients and controls. Patients with active RA had significantly higher percentage of CD3+/CD134+, CD4+/CD 134+, CD8+/CD134+ and CD25+/CD 134+ than those with inactive disease.
CONCLUSION: These findings suggest that CD134+ T cells are involved in the immunopathological process of RA synovitis, maybe mirroring some other autoimmune disease in which autoreactive T cell infiltrating the target tissues largely coexpress CD134.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407087

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  16 in total

Review 1.  Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets.

Authors:  Alison M Gizinski; David A Fox; Sujata Sarkar
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-08       Impact factor: 4.098

2.  A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

Authors:  Angela D Pardee; Dustin McCurry; Sean Alber; Peisheng Hu; Alan L Epstein; Walter J Storkus
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

3.  Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis.

Authors:  Zhao Xiaoyan; R Pirskanen; V Malmstrom; A K Lefvert
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 4.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

5.  Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells.

Authors:  F S Kalthoff; J Chung; A Stuetz
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

6.  Prenatal alcohol exposure alters the course and severity of adjuvant-induced arthritis in female rats.

Authors:  Xingqi Zhang; Ni Lan; Paxton Bach; David Nordstokke; Wayne Yu; Linda Ellis; Gary G Meadows; Joanne Weinberg
Journal:  Brain Behav Immun       Date:  2011-12-01       Impact factor: 7.217

7.  The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases.

Authors:  D S Vinay; B S Kwon
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

Review 8.  Control of immunity by the TNFR-related molecule OX40 (CD134).

Authors:  Michael Croft
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

9.  Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus.

Authors:  Sebastian Dolff; Daniel Quandt; Benjamin Wilde; Thorsten Feldkamp; Fan Hua; Xin Cai; Christof Specker; Andreas Kribben; Cees G M Kallenberg; Oliver Witzke
Journal:  Arthritis Res Ther       Date:  2010-07-23       Impact factor: 5.156

10.  Pathogenic roles of CD14, galectin-3, and OX40 during experimental cerebral malaria in mice.

Authors:  Miranda S Oakley; Victoria Majam; Babita Mahajan; Noel Gerald; Vivek Anantharaman; Jerrold M Ward; Lawrence J Faucette; Thomas F McCutchan; Hong Zheng; Masaki Terabe; Jay A Berzofsky; L Aravind; Sanjai Kumar
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.